Literature DB >> 25902874

MK-801 and amphetamine result in dissociable profiles of cognitive impairment in a rodent paired associates learning task with relevance for schizophrenia.

John Talpos1, Nancy Aerts2, Jason Waddell2, Thomas Steckler2.   

Abstract

RATIONALE: Paired associates learning (PAL) has been suggested to be predictive of functional outcomes in first episode psychosis and of conversion from mild cognitive impairment to Alzheimer's disease. An automated touch screen-based rodent PAL (rPAL) task has been developed and is sensitive to manipulations of the dopaminergic and glutamatergic system. Accordingly, rPAL when used with pharmacological models of schizophrenia, like NMDA receptor blockade with MK-801 or dopaminergic stimulation with amphetamine, may have utility as a translational model of cognitive impairment in schizophrenia.
OBJECTIVE: The purpose of this study was to determine if amphetamine- and MK-801-induced impairment represent distinct models of cognitive impairment by testing their sensitivity to common antipsychotics and determine the relative contributions of D1 versus D2 receptors on performance of PAL.
METHOD: Rats were trained in rPAL and were then treated with MK-801, amphetamine, risperidone, haloperidol, quinpirole, SK-82958, or SCH-23390 alone and in combination.
RESULTS: While both amphetamine and MK-801 caused clear impairments in accuracy, MK-801 induced a profound "perseverative" type behavior that was more pronounced when compared to amphetamine. Moreover, amphetamine-induced impairments, but not the effects of MK-801, could be reversed by antipsychotics as well as the D1 receptor antagonist SCH-23390, suggesting a role for both the D1 and D2 receptor in the amphetamine impairment model.
CONCLUSIONS: These data suggest that amphetamine and MK-801 represent dissociable models of impairment in PAL, dependent on different underlying neurobiology. The ability to distinguish dopaminergic versus glutamatergic effects on performance in rPAL makes it a unique and useful tool in the modeling of cognitive impairments in schizophrenia.

Entities:  

Keywords:  Dopamine receptor; Memory; NMDA receptor; Operant; PAL; Schizophrenia; Touch screen

Mesh:

Substances:

Year:  2015        PMID: 25902874     DOI: 10.1007/s00213-015-3934-x

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  24 in total

Review 1.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

2.  Visuospatial learning and executive function are independently impaired in first-episode psychosis.

Authors:  Jennifer H Barnett; Barbara J Sahakian; Ursula Werners; Katherine E Hill; Rossa Brazil; Olwyn Gallagher; Edward T Bullmore; Peter B Jones
Journal:  Psychol Med       Date:  2005-07       Impact factor: 7.723

Review 3.  Does the dopamine hypothesis explain schizophrenia?

Authors:  Chi-Ieong Lau; Han-Cheng Wang; Jung-Lung Hsu; Mu-En Liu
Journal:  Rev Neurosci       Date:  2013       Impact factor: 4.353

4.  The pharmacological sensitivity of a touchscreen-based visual discrimination task in the rat using simple and perceptually challenging stimuli.

Authors:  J C Talpos; A C Fletcher; C Circelli; M D Tricklebank; S L Dix
Journal:  Psychopharmacology (Berl)       Date:  2011-11-26       Impact factor: 4.530

Review 5.  Predicting drug efficacy for cognitive deficits in schizophrenia.

Authors:  Jim J Hagan; Declan N C Jones
Journal:  Schizophr Bull       Date:  2005-09-21       Impact factor: 9.306

Review 6.  Testing long-term memory in animal models of schizophrenia: suggestions from CNTRICS.

Authors:  Timothy J Bussey; Deanna M Barch; Mark G Baxter
Journal:  Neurosci Biobehav Rev       Date:  2013-06-18       Impact factor: 8.989

Review 7.  Schizophrenia and glutamatergic transmission.

Authors:  C A Tamminga
Journal:  Crit Rev Neurobiol       Date:  1998

8.  Assessing cognitive function in clinical trials of schizophrenia.

Authors:  Jennifer H Barnett; Trevor W Robbins; Verity C Leeson; Barbara J Sahakian; Eileen M Joyce; Andrew D Blackwell
Journal:  Neurosci Biobehav Rev       Date:  2010-01-25       Impact factor: 8.989

Review 9.  A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters.

Authors:  S D Robertson; H J G Matthies; A Galli
Journal:  Mol Neurobiol       Date:  2009-02-06       Impact factor: 5.590

Review 10.  The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue.

Authors:  Ralf Brisch; Arthur Saniotis; Rainer Wolf; Hendrik Bielau; Hans-Gert Bernstein; Johann Steiner; Bernhard Bogerts; Katharina Braun; Anna Katharina Braun; Zbigniew Jankowski; Jaliya Kumaratilake; Jaliya Kumaritlake; Maciej Henneberg; Tomasz Gos
Journal:  Front Psychiatry       Date:  2014-05-19       Impact factor: 4.157

View more
  8 in total

1.  Effects of the T-type calcium channel antagonist Z944 on paired associates learning and locomotor activity in rats treated with the NMDA receptor antagonist MK-801.

Authors:  Andrew J Roebuck; Wendie N Marks; Max C Liu; Nimra B Tahir; Nadine K Zabder; Terrance P Snutch; John G Howland
Journal:  Psychopharmacology (Berl)       Date:  2018-09-24       Impact factor: 4.530

Review 2.  Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia.

Authors:  Cassandra J Hatzipantelis; Monica Langiu; Teresa H Vandekolk; Tracie L Pierce; Jess Nithianantharajah; Gregory D Stewart; Christopher J Langmead
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-28

3.  Differential effects of d- and l-enantiomers of govadine on distinct forms of cognitive flexibility and a comparison with dopaminergic drugs.

Authors:  Gemma L Dalton; Stan B Floresco; Anthony G Phillips
Journal:  Psychopharmacology (Berl)       Date:  2021-01-11       Impact factor: 4.530

4.  Effects of D- and L-govadine on the disruption of touchscreen object-location paired associates learning in rats by acute MK-801 treatment.

Authors:  Brittney R Lins; Anthony G Phillips; John G Howland
Journal:  Psychopharmacology (Berl)       Date:  2015-09-11       Impact factor: 4.530

5.  Dissociable effects of NR2A and NR2B NMDA receptor antagonism on cognitive flexibility but not pattern separation.

Authors:  Gaurav Kumar; Joseph Olley; Thomas Steckler; John Talpos
Journal:  Psychopharmacology (Berl)       Date:  2015-07-18       Impact factor: 4.530

6.  Superior effects of quetiapine compared with aripiprazole and iloperidone on MK-801-induced olfactory memory impairment in female mice.

Authors:  Ahmet Mutlu; Oguz Mutlu; Guner Ulak; Furuzan Akar; Havva Kaya; Faruk Erden; Pelin Tanyeri
Journal:  Biomed Rep       Date:  2017-03-23

7.  Stimulant drug effects on touchscreen automated paired-associates learning (PAL) in rats.

Authors:  Corinna Roschlau; Angeline Votteler; Wolfgang Hauber
Journal:  Learn Mem       Date:  2016-07-15       Impact factor: 2.460

8.  Partial mGlu5 Negative Allosteric Modulator M-5MPEP Demonstrates Antidepressant-Like Effects on Sleep Without Affecting Cognition or Quantitative EEG.

Authors:  Kimberly M Holter; Alex D Lekander; Christina M LaValley; Elizabeth G Bedingham; Bethany E Pierce; L Paul Sands; Craig W Lindsley; Carrie K Jones; Robert W Gould
Journal:  Front Neurosci       Date:  2021-07-02       Impact factor: 4.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.